YES, WE CAN
Our goal is simple, to improve lives by increasing access to medicines around the world.
We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:
- Provide access to medicines for patients in need
- Demonstrate the value of new medications
- Enable better health
YES, WE WILL
Our commitment is unwavering.
We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.
YES, WE DID
Reduce the risk of infection in leukemia patients.
LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.
YES, WE DID
Provide free cancer treatment to patients around the world
The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.Read More
YES, WE DID
Uninterrupted distribution to patients in Latin America
A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.Read More
YES, WE DID
Assuring continuity during a global pandemic
A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.Read More
Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!
They are a prime example on how Pharma should be running their business and focusing their motivation.Joshua Frase Foundation
PROVIDING ACCESS TO
countries with the help of our non-profit collaborators:
RECENT NEWS & EVENTS
Berlin, 27 January 2021 – Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro…Read More
Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)
SALT LAKE CITY and CHARLOTTE, N.C., Dec. 1, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, announced today that they have launched a global…Read More
(Repost from ZNM) Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner…Read More
Max Global Experience: Uganda
Tanner Pharma Group is proud to serve as the title sponsor for The Max Foundation’s 2018 “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.